Drug company Mylan was forced to recall its EpiPen allergy treatment across the U.S., after two reported instances of the device failing to release its medicine. The recall comes as EpiPen is fast losing market share to generic rivals, to the delight of politicians who accused Mylan of price-gouging last year after it raised the price by 500%. Mylan had already paid $465 million to make that scandal go away. Given the hit to consumer loyalty generated by last year's scandal, the recall risks hastening the decline in EpiPen's value to Mylan. Fortune